• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Origin treats first patients in study of nitric oxide for diabetic foot ulcers

March 22, 2017 By Sarah Faulkner

Origin treats first patients in study of nitric oxide for diabetic foot ulcersOrigin said today that it treated the 1st patients in its dose-ranging Genesis Phase IIb-equivalent trial. The study is evaluating therapeutic quantities of plasma-generated nitric oxide as a treatment for chronic diabetic foot ulcers.

The 27-week trial is slated to enroll up to 100 patients. Patients will be randomized into 1 of 4 dosing regimens, or receive standard of care as a control, to assess the safety and efficacy of plasma-generated nitric oxide, according to Origin. The company plans to treat the participants for 12 weeks and monitor them for 12 weeks following treatment.

One group of patients will receive a 6 minute dose of nitric oxide twice per week, while another group will receive 6 minutes 4 times a week. Another arm will be treated with 12 minutes of nitric oxide twice per week and the final arm will receive 12 minutes 4 times a week. All patients will be treated with the standard of care, including dressing changes, wound cleansing, pressure relief and wound debridement, Origin reported.

The company said it will measure the effectiveness of its therapy according to wound closure rate and wound closure percentage. Origin also plans to monitor and report any wound-related adverse events.

“Diabetes and consequential diabetic foot ulcers are a growing healthcare burden impacting millions of people,” chairman & CEO Michael Preston said in prepared remarks. “Plasma-generated nitric oxide has the potential to offer a new safe and effective therapy to close wounds actively, serving a large unmet need. This marks another step forward in our mission to become the advanced therapy of choice for the treatment of DFUs. We look forward to providing an update and initial readout of the interim results in the 4th quarter of 2017.”

Filed Under: Clinical Trials, Diabetes, Featured, Wall Street Beat, Wound Care Tagged With: Origin

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS